Heterobifunctional PEG with Acid-Labile Groups for Drug Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for heterobifunctionalized poly(ethylene glycol) compounds with various terminal functional groups to enhance the therapeutic applications, particularly in pharmaceutical and biomedical fields, where PEGylation is used to improve drug solubility and biodistribution profiles.
Innovation Solution
The development of compounds with specific functional groups, such as those described in formulas I, II, III, and IV, which include a range of terminal functional groups that can be used for PEGylation, allowing for the attachment of different moieties and improving the properties of biomolecules and drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PEGylation is used to improve drug solubility and biodistribution, then therapeutic applications are enhanced, but the need for heterobifunctionalized compounds with various terminal functional groups increases complexity
Solution Approach 1:
The patent creates heterobifunctionalized PEG compounds where one end contains a carboxylic acid group for protein conjugation and the other end contains diverse functional groups (alcohols, amines, carboxylic acids, hydroxycarbonyls, isocyanates, hydrazides, hydroxysulfonic acids, sulfonic acids, phosphonic acids, phosphates) for various therapeutic applications. This multi-functional design allows a single PEG backbone to serve multiple purposes: improving solubility, enabling protein conjugation, and providing diverse attachment points for drugs or biomolecules, thereby resolving the contradiction between enhanced therapeutic applications and increased structural complexity.
2Adaptability or versatility
If various terminal functional groups are introduced for PEGylation, then versatility is improved, but manufacturing complexity increases
Solution Approach 1:
The patent divides the PEG molecule into distinct functional segments: a carboxylic acid-containing end group for protein conjugation and a separate diverse functional group at the other end for specific therapeutic applications. This segmentation allows each end to be optimized independently and enables modular synthesis approaches where different functional groups can be introduced at different stages, reducing overall manufacturing complexity while maintaining versatility.
Solution Approach 2:
The patent employs preliminary protection and deprotection strategies during synthesis, where functional groups are temporarily protected during certain synthesis steps and then deprotected to reveal the desired terminal groups. This preliminary action approach allows for the systematic building of complex heterobifunctionalized PEG compounds from simpler precursors, making the manufacturing process more manageable despite the diversity of terminal groups.
Data Source
AI summary
The present invention provides bifunctional polymers, methods of preparing the same, and intermediates thereto. These compounds are useful in a variety of applications including the PEGylation of biologically active molecules. The invention also provides methods of using said compounds and compositions thereof.